Viewing nowCombinationYusitamet XR Extended-Release Tablets 100/1000 Milligrams
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Yu Young Pharmaceutical Co., Ltd.

MFDS item code 202201931 · Approved 2022.05.11 · Insurance code 648204580
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in patients with type 2 diabetes to improve blood sugar control in conjunction with dietary management and exercise by combining sitagliptin and metformin.
In antidiabetic therapy, the dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients who have been receiving immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).
This medication consists of sitagliptin and metformin and is used for the treatment of diabetes. During treatment, severe allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a healthcare professional. Additionally, serious inflammation of the pancreas (pancreatitis) may develop, so if symptoms such as abdominal pain, nausea, or vomiting occur, visit the hospital immediately. Patients with severe kidney dysfunction, acute heart failure, severe infections, or dehydration should not use this medication, and should temporarily stop taking it when undergoing tests with contrast agents. It is advisable not to take this medication if pregnant or if there is a possibility of pregnancy, and it is also not recommended for nursing mothers. This medication can cause lactic acidosis, a rare but potentially fatal metabolic complication, so if unexpected muscle pain, difficulty breathing, fatigue, abdominal pain, or lethargy occurs, inform a healthcare provider immediately. Symptoms of hypoglycemia, such as low blood sugar, may also occur, so it is important to avoid skipping meals or excessive exercise, and take appropriate actions if hypoglycemia is suspected. During treatment, regular checks of kidney function and blood tests are recommended to ensure safety, and it is advisable to check vitamin B12 levels periodically. Consumption of alcohol can increase the risk of side effects from this medication, so it should be avoided. If undergoing surgery or in poor condition due to severe infections or trauma, the medication should be temporarily stopped and restarted once health is restored. Take care not to take other medications or dietary supplements without consulting a physician during treatment with this medication. Finally, this medication has not established safety and effectiveness in children under 18 years of age, therefore it is preferable not to use it.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, joint pain accompanied by severe and disabling symptoms, vesiculobullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent exposure to air or moisture, and keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication over time.
Light blue, oval-shaped, biconvex extended-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Yu Young Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.